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Case Report
Phentolamine Mesylate can alleviate the nausea and
vomiting associated with liver metastasis
G J McCleane
Nauseaandvomiting arecommon symptoms in a
patient with cancer. They may be due directly to
thetumouritselformaybesideeffectsoftreatment
given,thisbeingaimedatachievingeitherdisease
remission or symptom relief. With the advent of
new anti-emetic agents, such as the anti 5HT3
class ofdrugs, treatmentfornauseaandvomiting
can be more specifically targeted to the causal
factor.
Among factors that can induce nausea and
vomitingarelivermetastaticdeposits. Thenausea
and vomiting produced by hepatic secondaries
can respond to "conventional" anti-emetics but
on occasions can be resistant to such treatment
and necessitate the use ofdexamethasone which
can be highly effective but takes 24-48 hours to
havethedesiredeffect. Obviouslythistimedelay
is unpleasant for the patient and reduces the
quality oflife when quantity of life is restricted.
The following two case reports highlight the
potential beneficial effects of intravenous
phentolamine in achieving symptom control
rapidly and buying time for the more prolonged
effects of dexamethasone to become apparent.
CASE1 A40 yearold female was referred with
intractable nausea and vomiting unresponsive to
metoclopramide, cyclizine and ondansetron. She
had an inoperable gastric carcinoma with liver
secondaries, and no radiological or endoscopic
evidence ofobstruction. Her liver was enlarged.
An initial intravenous bolus of 10 mg of
phentolamine was given which removed nausea
within minutes. This was followed by a bolus of
16 mg of dexamethasone intravenously and a
reducing course of oral dexamethasone starting
at 8 mg/day.
This patient had good relieffor five days but was
unfortunately unable to tolerate the
dexamethasone which was stopped after 3 days.
Atthisstageafurther 10mgbolusofphentolamine
was given with good immediate effect and she
was commenced on an intravenous infusion of
phentolamine (15 mg/24 hrs) via asyringe driver
(Graseby Ltd). After 24 hours the cannula had to
be removed due to phlebitis and was replaced by
a 15 cm cannula (Vygon Leaderflex) and the
infusion recommenced with good effect.
CASE 2 A 77 year old lady was referred with
nausea and vomiting associated with aneoplasm
involving the head of the pancreas with
secondaries in the porta hepatis and liver which
were diagnosed at laparotomy. No bowel
obstruction was noted. A choledocojejunostomy
wasperformedbecauseofadistendedgallbladder.
Treatment with metoclopramide and cyclizine
was unsuccessful.
On examination she had a tender enlarged liver
and was jaundiced. An intravenous injection of
10 mg phentolamine gave relief of nausea in
minutes. This treatment was followed by 16 mg
intravenously of dexamethasone and an oral
reducing course ofdexamethasone commencing
at8 mgdaily in divideddoses overa9dayperiod.
There was no return ofnausea or vomiting in the
subsequent 4 weeks until her demise.
DISCUSSION
Phentolamine is a short-acting parenteral alpha
blocker which in the past was mainly used in
anaesthetic practice as a vasodilator/anti-
hypertensive. More recently it has been used in
thediagnosis ofsympathetically maintainedpain.
It has a short half-life but when used to diagnose
sympathetically maintained pain its beneficial
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effect can last forup to 48 hours. The etiology of
the nausea and vomiting associated with liver
secondaries isnotentirelyclearbutmay berelated
to stretching of the sympathetically innervated
livercapsule (viathe hepatic plexus, a derivative
of the coeliac plexus,2) giving rise not only to
nausea and vomiting but also to abdominal pain.
Dexamethasone would be expected to have a
beneficialeffectbyreducingperi-tumouroedema
and hence stretch on the capsule. On this basis it
may be that the blockade of sympathetic nerves
around the liver capsule produced by
phentolamine is acauseofthereduction innausea
and vomiting associated with this agent. The
transient hypotension which accompanies its use
(caused by a similar blockade of vascular
sympathetic fibres) is rarely troublesome '4 and
does not often require intervention. Palpitations
may occur but again are short lived.
Perhaps the most marked drawback to
phentolamineistheneedtoadministeritparentally
but despite this it has proved to be a major asset
in acute management ofthe nausea and vomiting
associated with liver secondaries and as such
merits further investigation.
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